Effect of Chitosan Coating on PLGA Nanoparticles for Oral Delivery of Thymoquinone: In Vitro, Ex Vivo, and Cancer Cell Line Assessments
Source abstract
Abstract
In the present study, thymoquinone (TQ)-encapsulated chitosan- (CS)-coated poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) were formulated using the emulsion evaporation method. NPs were optimized by using 33-QbD approach for improved efficacy against breast cancer. The optimized thymoquinone loaded chitosan coated Poly (d,l-lactide-co-glycolide) nanoparticles (TQ-CS-PLGA-NPs) were successfully characterized by different in vitro and ex vivo experiments as well as evaluated for cytotoxicity in MDA-MB-231 and MCF-7 cell lines. The surface coating of PLGA-NPs was completed by CS coating and there were no significant changes in particle size and entrapment efficiency (EE) observed. The developed TQ-CS-PLGA-NPs showed particle size, polydispersibility index (PDI), and %EE in the range between 126.03–196.71 nm, 0.118–0.205, and 62.75%–92.17%. The high and prolonged TQ release rate was achieved from TQ-PLGA-NPs and TQ-CS-PLGA-NPs. The optimized TQ-CS-PLGA-NPs showed significantly higher mucoadhesion and intestinal permeation compared to uncoated TQ-PLGA-NPs and TQ suspension. Furthermore, TQ-CS-PLGA-NPs showed statistically enhanced antioxidant potential and cytotoxicity against MDA-MB-231 and MCF-7 cells compared to uncoated TQ-PLGA-NPs and pure TQ. On the basis of the above findings, it may be stated that chitosan-coated TQ-PLGA-NPs represent a great potential for breast cancer management.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nigella sativa pharmacological applications · Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
Department of Pharmaceutical Sciences, College of Pharmacy, Almaarefa University, Riyadh 11597, Saudi Arabia
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India
Genome Biology Laboratory, Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India
Funding
Deputyship for Research & Innovation, “Ministry of Education
References (49)
Show source-provided references
1. Breast cancer in low-middle income countries: Abnormality in splicing and lack of targeted treatment options
2. Polymer-lipid hybrid nanoparticles: A next-generation nanocarrier for targeted treatment of solid tumors10.2174/1381612826666200116150426 ↗
3. Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via nanostructured lipid carrier (NLC) formulation10.1208/s12249-015-0391-0 ↗
4. Thymoquinone, as an anticancer molecule: From basic research to clinical investigation10.18632/oncotarget.17206 ↗
5. Thymoquinone-based nanotechnology for cancer therapy: Promises and challenges10.1016/j.drudis.2018.01.043 ↗
6. Polymeric Nanomedicines in Treatment of Breast Cancer: Review of Contemporary Research10.2174/9789811422133120110004 ↗
7. PLGA-based nanoparticles: An overview of biomedical applications10.1016/j.jconrel.2012.01.043 ↗
8. PLGA-Based Nanoparticles in Cancer Treatment10.3389/fphar.2018.01260 ↗
9. Drug-loaded PLGA nanoparticles for oral administration: Fundamental issues and challenges ahead10.1615/CritRevTherDrugCarrierSyst.v29.i2.20 ↗
10. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin10.1016/j.colsurfb.2015.11.033 ↗
11. Preparation and characterization of insulin loaded bioadhesive PLGA nanoparticles for oral administration10.1016/j.ejps.2012.01.002 ↗
12. Chitosan modified PLGA nanoparticles with versatile surface for improved drug delivery10.1208/s12249-013-9943-3 ↗
13. Cellular uptake, antioxidant and antiproliferative activity of entrapped α-tocopherol and γ-tocotrienol in poly(lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles(PLGA-Chi)10.1016/j.jcis.2014.12.083 ↗
14. Mucoadhesive chitosan-coated PLGA nanoparticles for oral delivery of ferulic acid10.1080/21691401.2018.1477788 ↗
15. Curcumincontaining chitosan nanoparticles as a potential mucoadhesive delivery system to the colon10.3109/10837450.2011.640688 ↗
16. Formulation and evaluation of thymoquinone niosomes: Application of developed and validated RP-HPLC method in delivery system10.1080/03639045.2019.1660366 ↗
17. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers10.1080/1061186X.2016.1191080 ↗
18. Cilnidipine loaded transfersomes for transdermal application: Formulation optimization, in-vitro and in-vivo study10.1016/j.jddst.2019.101303 ↗
19. In vitro–in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin10.2147/IJN.S213836 ↗
20. Optimization to development of chitosan decorated polycaprolactone nanoparticles for improved ocular delivery of dorzolamide: In vitro, ex vivo and toxicity assessments10.1016/j.ijbiomac.2020.09.185 ↗
21. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment10.1016/j.jddst.2020.101634 ↗
22. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability10.1016/j.colsurfb.2017.03.006 ↗
23. Polymer-lipid hybrid nanoparticles as enhanced indomethacin delivery systems10.1016/j.ejps.2018.05.014 ↗
24. Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: In vitro, ex vivo and in vivo assessments10.1080/21691401.2017.1408124 ↗
25. Mucoadhesive chitosan-coated liposomes: Characteristics and stability10.1080/026520401750038557 ↗
26. Formulation of thymoquinone loaded chitosan nano vesicles: In-vitro evaluation and in-vivo anti-hyperlipidemic assessment10.1016/j.jddst.2019.01.033 ↗
27. Imam, S.S., Alshehri, S., Alzahrani, T.A., Hussain, A., and Altamimi, M.A. (2020). Formulation and Evaluation of Supramolecular Food-Grade Piperine HP β CD and TPGS Complex: Dissolution, Physicochemical Characterization, Molecular Docking, In Vitro Antioxidant Activity, and Antimicrobial Assessment. Molecules, 25.10.3390/molecules25204716 ↗
28. Characterization and carboplatin loaded chitosan nanoparticles for the chemotherapy against breast cancer in vitro studies10.1016/j.ijbiomac.2016.12.090 ↗
29. The effects of chemotherapeutic drugs on viabilty, apoptosis, and survivin expression in MCF-7 cells10.1267/ahc.38.323 ↗
30. Formulation of sitagliptin-loaded oral polymeric nano scaffold: Process parameters evaluation and enhanced anti-diabetic performance10.1080/21691401.2017.1411933 ↗
31. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma10.1208/s12249-019-1304-4 ↗
32. Nanoprecipitation and the “Ouzo effect”: Application to drug delivery devices10.1016/j.addr.2013.12.009 ↗
33. Surface-coated polycaprolactone nanoparticles with pharmaceutical application: Structural and molecular mobility evaluation by TD-NMR10.1016/j.polymertesting.2017.01.032 ↗
34. Improvement of Ocular Efficacy of Levofloxacin by Bioadhesive Chitosan Coated PLGA Nanoparticles: Box-behnken Design, In-vitro Characterization, Antibacterial Evaluation and Scintigraphy Study
35. Carvedilolnano lipid carriers: Formulation, characterization and in-vivo evaluation10.3109/10717544.2016.1165314 ↗
36. Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: Statistical design, characterization and in vivo studies10.1016/j.ijbiomac.2018.04.122 ↗
37. Effect of process and formulation variables on the preparation of parenteral paclitaxel-loaded biodegradable polymeric nanoparticles: A cosurfactant study10.1016/j.ajps.2015.09.004 ↗
38. Optimization of paclitaxel loaded poly (ε-caprolactone) nanoparticles using Box Behnken design
39. Development and Statistical Optimization of Solid Lipid Nanoparticles of Simvastatin by Using 2(3) Full-Factorial Design10.1208/s12249-010-9414-z ↗
40. Effect of particle size on oral absorption of carvedilol nanosuspensions: In vitro and in vivo evaluation10.2147/IJN.S87143 ↗
41. Lu, B., Lv, X., and Le, Y. (2019). Chitosan-modified PLGA nanoparticles for control-released drug delivery. Polymers, 11.10.3390/polym11020304 ↗
42. Polymeric micelles for oral drug administration enabling locoregional and systemic treatments10.1517/17425247.2015.960841 ↗
43. Preparation of sustained release apremilast-loaded PLGAnanoparticles: In vitro characterization and in vivo pharmacokinetic study in rats10.2147/IJN.S195048 ↗
44. The intracellular uptake ability of chitosan-coated poly (d,l-lactideco-glycolide) nanoparticles10.1007/s12272-001-1267-5 ↗
45. Why is chitosan mucoadhesive?10.1021/bm800276d ↗
46. Antioxidant and antimicrobial activities of various solvent extracts, piperine and piperic acid from Piper nigrum10.1016/j.lwt.2012.07.036 ↗
47. Chitosan coated PLGA nanoparticles: A sustained drug release strategy for cell cultures10.1016/j.colsurfb.2012.10.063 ↗
48. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa)10.1155/2015/263131 ↗
49. Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: Formulation design, biodistribution, and γ-scintigraphy imaging10.1155/2014/984756 ↗